ArticleCancer science2013
Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.
Article in Cancer science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Immune landscape of neoadjuvant chemoradiotherapy: involvement of MAL, a T-cell differentiation protein.Oncology research · 2025Article
- Tertiary lymphoid structures in cancer: maturation and induction.Frontiers in immunology · 2024Review
- The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.Journal of cancer research and clinical oncology · 2023Article
- Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.BMC cancer · 2022Article
- Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.World journal of gastroenterology · 2022Review
- Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer.EBioMedicine · 2022Article
- Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.British journal of cancer · 2022Article
- Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.Frontiers in immunology · 2022Review
- The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.Cancer science · 2021Article
- Immunomodulation in Pancreatic Cancer.Cancers · 2020Review
- A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy.Translational lung cancer research · 2020Review
- The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection.Annals of surgical oncology · 2020Article
- Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.Cancer science · 2019Article
- Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.Journal of gastrointestinal oncology · 2018Review
- CAR T-cell therapy for pancreatic cancer.Journal of surgical oncology · 2017Review
- Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.World journal of gastrointestinal oncology · 2016Review
- Postoperative Regulatory T-Cells and Natural Killer Cells in Stage I Nonsmall Cell Lung Cancer Underwent Video-assisted Thoracoscopic Lobectomy or Thoracotomy.Chinese medical journal · 2015Article
- The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.International journal of clinical oncology · 2015Article
- Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.Cancer science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is an aggressive cancer with poor prognosis. Little is known about the immune response in the tumor microenvironment after chemotherapy for initially unresectable tumor. The purpose of this study was to investigate the immunological effects of chemoradiation therapy in the tumor microenvironment of pancreatic adenocarcinoma. Seventeen patients with pancreatic adenocarcinoma with and without preoperative chemoradiation therapy were retrospectively analyzed using immunohistochemical methods for HLA class I heavy chain, CD4(+), CD8(+), CD45RO(+) and Foxp3(+) T cell infiltrations. Seven of the 17 study patients received preoperative chemoradiation therapy. There were no statistically significant differences in the number of CD4(+) and CD8(+) T cell infiltrations in the tumor microenvironment. However, the number of Foxp3(+) T cell infiltrations was significantly lower in the neoadjuvant chemoradiation therapy group. The HLA class I expression status was the same between the two groups. In conclusion, preoperative chemoradiation therapy in pancreatic adenocarcinoma is useful for reducing regulatory T cell levels in combination with its direct cytotoxic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.